Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H R Roberts

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Journal of the American Dietetic Association|July 1, 1980
Calcium, phosphorus, iron, iodine, and zinc in the "total diet"B F Harland, R D Johnson, E M Blendermann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 24, 1999
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study GroupJ M Lusher, H R Roberts, G Davignon, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1986
Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIIIY Sultan, G C White, A Aronstam, et al.
Blood|June 15, 1994
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factorS Chaing, B Clarke, S Sridhara, et al.
The Journal of Biological Chemistry|March 10, 1985
Structural and functional characteristics of activated human factor IX after chemical modification of gamma-carboxyglutamic acid residuesD L Straight, G B Sherrill, C M Noyes, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|December 1, 1990
Calcium ion binding to human and bovine factor XD M Monroe, D W Deerfield, D L Olson, et al.
Clinical Pharmacology and Therapeutics|June 1, 1994
Pharmacokinetics and pharmacodynamics of recombinant factor VIIaC M Lindley, W T Sawyer, B G Macik, et al.
Progress in Clinical and Biological Research|January 1, 1984
Panel discussion on the treatment of patients with factor VIII inhibitorsJ M Lusher, M E Eyster, M W Hilgartner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 20, 2008
Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitorsW K Hoots, L S Ebbesen, B A Konkle, et al.
The Journal of Biological Chemistry|July 15, 1990
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg")H H Watzke, K Lechner, H R Roberts, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Journal of the American Dietetic Association|July 1, 1980
Calcium, phosphorus, iron, iodine, and zinc in the "total diet"B F Harland, R D Johnson, E M Blendermann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 24, 1999
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study GroupJ M Lusher, H R Roberts, G Davignon, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1986
Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIIIY Sultan, G C White, A Aronstam, et al.
Blood|June 15, 1994
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factorS Chaing, B Clarke, S Sridhara, et al.
The Journal of Biological Chemistry|March 10, 1985
Structural and functional characteristics of activated human factor IX after chemical modification of gamma-carboxyglutamic acid residuesD L Straight, G B Sherrill, C M Noyes, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|December 1, 1990
Calcium ion binding to human and bovine factor XD M Monroe, D W Deerfield, D L Olson, et al.
Clinical Pharmacology and Therapeutics|June 1, 1994
Pharmacokinetics and pharmacodynamics of recombinant factor VIIaC M Lindley, W T Sawyer, B G Macik, et al.
Progress in Clinical and Biological Research|January 1, 1984
Panel discussion on the treatment of patients with factor VIII inhibitorsJ M Lusher, M E Eyster, M W Hilgartner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 20, 2008
Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitorsW K Hoots, L S Ebbesen, B A Konkle, et al.
The Journal of Biological Chemistry|July 15, 1990
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg")H H Watzke, K Lechner, H R Roberts, et al.
Pageof 19